A/Prof. Xiaojie Wu (Shanghai, China)
A/Prof. Xiaojie Wu is the Deputy Director of Clinical Pharmacology Research Center at Huashan Hospital affiliated with Fudan University. She holds significant roles in various academic and professional societies, including Deputy Chairman of the Oncology Clinical Research Training Base of the China Medical Education Association and Vice Chairman of the Youth Committee of the Drug Clinical Trial professional Committee of the Chinese Pharmacological Society. She is also an active member of several other pharmacological committees and workgroups, including DIA Clinical Pharmacology Community.
A/Prof.. Wu is a distinguished researcher specializing in early clinical studies of innovative drugs and clinical pharmacology. She has participated in over 170 phase I clinical trials and has led or co-led more than 30 phase I and II trials. A/Prof.. Wu has extensive experience in clinical trial design and protocol development. She has been a visiting scholar at the Royal Danish Hospital and completed the Harvard Global Clinical Scholars Research Training (GCSRT) program. In 2015, she was seconded to the NMPA Drug Evaluation Center and Human Genetic Resources Management Office, and she worked as a part-time reviewer of the General Department of NMPA Drug Evaluation Center. She also worked on human genetic resource management with the Ministry of Science and Technology in 2019.
She has published over 60 research papers, with 15 as first or corresponding author in the past five years, including 13 indexed by SCI. A/Prof. Wu has contributed as editor and deputy editor to 2 key textbook, Pharmacokinetics and Pharmacodynamics: Concepts and Applications, and Drug Clinical Research Theory and Practice. A/Prof. Wu holds grants from Shanghai Science and Technology Committee. She has been main contributor major projects of the 13th Five-Year Plan and key research and development plans of the Ministry of Science and Technology. She has received numerous awards, including the Second Prize of the Chinese Pharmaceutical Association Science and Technology Award (2023).
A/Prof. Xiaojie Wu is the Deputy Director of Clinical Pharmacology Research Center at Huashan Hospital affiliated with Fudan University. She holds significant roles in various academic and professional societies, including Deputy Chairman of the Oncology Clinical Research Training Base of the China Medical Education Association and Vice Chairman of the Youth Committee of the Drug Clinical Trial professional Committee of the Chinese Pharmacological Society. She is also an active member of several other pharmacological committees and workgroups, including DIA Clinical Pharmacology Community.
A/Prof.. Wu is a distinguished researcher specializing in early clinical studies of innovative drugs and clinical pharmacology. She has participated in over 170 phase I clinical trials and has led or co-led more than 30 phase I and II trials. A/Prof.. Wu has extensive experience in clinical trial design and protocol development. She has been a visiting scholar at the Royal Danish Hospital and completed the Harvard Global Clinical Scholars Research Training (GCSRT) program. In 2015, she was seconded to the NMPA Drug Evaluation Center and Human Genetic Resources Management Office, and she worked as a part-time reviewer of the General Department of NMPA Drug Evaluation Center. She also worked on human genetic resource management with the Ministry of Science and Technology in 2019.
She has published over 60 research papers, with 15 as first or corresponding author in the past five years, including 13 indexed by SCI. A/Prof. Wu has contributed as editor and deputy editor to 2 key textbook, Pharmacokinetics and Pharmacodynamics: Concepts and Applications, and Drug Clinical Research Theory and Practice. A/Prof. Wu holds grants from Shanghai Science and Technology Committee. She has been main contributor major projects of the 13th Five-Year Plan and key research and development plans of the Ministry of Science and Technology. She has received numerous awards, including the Second Prize of the Chinese Pharmaceutical Association Science and Technology Award (2023).